ANNOVIS BIO

ANVSNYSE

🏆 #3881 by market capUS Equity

$1.88▼ $0.01 (−0.27%)

Live

1h▲ 0.5%

24h▼ 0.3%

7d▲ 0.3%

14d▲ 9.9%

30d▲ 8.0%

1y▼ 32.4%

🏦Market Cap

$65M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $1.87 – $1.91
52-Week Range: $1.54 – $5.50
Volume: $6.42B
Avg Volume: $5.64B
Shares Outstanding: 34.6M
Next Earnings: Sep 23, 2026

Fundamentals Snapshot

Annual Revenue: $5M
Last Q Revenue: $1M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.70
Dividend Yield: —

Why Investors Own ANVS

✓High-growth profile — revenue up -2.9% YoY with expanding US Equity exposure.
✓Healthy economics — 39% gross margin and 13% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$5M▼ −2.0% YoY

Gross Margin (TTM)

38.5%▲ +4.2% YoY

Operating Income (TTM)

$2M▼ −2.0% YoY

Free Cash Flow (TTM)

$721,991▼ −2.0% YoY

About ANNOVIS BIO

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.

🦦